Published in World J Gastroenterol on April 07, 2014
Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol (2015) 0.89
Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol (2016) 0.85
Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol (2015) 0.81
HCV E2 core structures and mAbs: something is still missing. Drug Discov Today (2014) 0.79
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection. Genes Immun (2015) 0.77
Plaque2.0-A High-Throughput Analysis Framework to Score Virus-Cell Transmission and Clonal Cell Expansion. PLoS One (2015) 0.76
The Roles of RNase-L in Antimicrobial Immunity and the Cytoskeleton-Associated Innate Response. Int J Mol Sci (2016) 0.76
A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes. Sci Rep (2016) 0.75
The unexpected structures of hepatitis C virus envelope proteins. Exp Ther Med (2017) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol (1993) 10.65
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Virus entry: open sesame. Cell (2006) 6.33
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Hepatitis C virus replication in mice with chimeric human livers. Nat Med (2001) 5.87
A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 5.02
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol (2006) 4.16
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med (2012) 3.89
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A (2009) 3.49
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem (2003) 2.82
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol (1999) 2.52
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
Assembly of infectious hepatitis C virus particles. Trends Microbiol (2010) 2.36
The epidermal growth factor receptor ligands at a glance. J Cell Physiol (2009) 2.35
The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 2.28
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology (2011) 2.24
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Membrane fusion activity of tick-borne encephalitis virus and recombinant subviral particles in a liposomal model system. Virology (2000) 2.09
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 2.06
Eph, a protein family coming of age: more confusion, insight, or complexity? Sci Signal (2008) 2.01
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol (2007) 1.95
Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J (2009) 1.90
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One (2008) 1.86
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis (2005) 1.74
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut (2014) 1.70
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol (2010) 1.64
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J Virol (2007) 1.59
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection. J Virol (2005) 1.53
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology (2011) 1.52
The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Cla1 is mediated by ApoB-containing lipoproteins. FASEB J (2006) 1.52
Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J Virol (2009) 1.44
Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A (2013) 1.43
Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol (2010) 1.42
Involvement of lipids in different steps of the flavivirus fusion mechanism. J Virol (2003) 1.42
Hepatitis C virus host cell entry. Curr Opin Virol (2012) 1.41
HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe (2013) 1.37
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology (2012) 1.34
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem (2006) 1.32
Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One (2009) 1.31
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology (2011) 1.28
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology (2012) 1.26
The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int J Biochem Cell Biol (2004) 1.26
Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 1.24
Hepatitis C virus entry: beyond receptors. Rev Med Virol (2012) 1.23
Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1. J Gen Virol (2007) 1.22
Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res (2007) 1.20
Structure of a pestivirus envelope glycoprotein E2 clarifies its role in cell entry. Cell Rep (2012) 1.18
Hepatitis C virus entry. Curr Top Microbiol Immunol (2013) 1.17
Characterization of the functional requirements of West Nile virus membrane fusion. J Gen Virol (2009) 1.17
Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol (2012) 1.14
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13
Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virol (2008) 1.12
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A (2009) 1.11
Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection. J Clin Invest (2002) 1.11
Crystal structure of glycoprotein E2 from bovine viral diarrhea virus. Proc Natl Acad Sci U S A (2013) 1.10
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol (2010) 1.10
Development of novel therapies for hepatitis C. Antiviral Res (2010) 1.09